This is an open-label, pilot, phase 1 study to determine the safety profile of anti-CD19 CAR-T cell infusion in participants with R/R B-cell NHL. The dose-finding cohorts in this study will evaluate and define the safe dose of anti-CD19 Chimeric antigen receptor T cells (CAR-T) cells. Using a "3+3" design, participants will be enrolled sequentially to each dose level. A dose expansion will then occur at the maximum tolerated dose (MTD) and dose levels that have not exceeded the MTD.
Sponsor
University of California, San Francisco
Status of enrollment
Accepting new patients
Ages Eligible for Study
Open to people ages 18 years and up
Genders Eligible for Study
Females and males
Disease indication
Non-Hodgkin Lymphoma
Principal Investigator
Charalambos Andreadis
Contact
Laurel Brechtel
Additional study eligibility details can be found at UCSF Clinical Trials.